In January–August 2022, Russia imported 535.5 billion rubles’ worth of ready-made pharmaceutical drugs (customs clearance and VAT included), up 9.4% from the same period in 2021. It was mainly the work in August that helped maintain positive growth rates. As for bulk drugs, the growth rate was 23.4%. In physical terms, the growth rates for both groups were negative. The import volume of ready-made drugs was around 1.1 billion packages, down 7.7% from January–August 2021. The import of bulk drugs was 983 million MDUs, down 34.6%.

In January–August 2022, Russia imported 134.1 billion rubles’ worth of APIs (customs clearance and VAT included), up only 5.2% from January–August 2021. In physical terms, the growth rate was as high as 25.3%, with 13,400 tons imported.

From January to August 2022, the offline sales of veterinary drugs in the Russian retail market were 14.2 billion RUB (retail prices, VAT included), down 5.4% from January–August 2021. In physical terms, the sales were 91.5 million minimum dosage units (MDU), down 21%.

In Q1–Q2 2022, the online sales or reservations of pharmacy products (pharmaceutical drugs and parapharmaceuticals) in Russia were 142.5 billion rubles (end-user prices, VAT included), comparable to the total in 2020. The growth rate was 51.3% against 69.6% in Q1 2022. The online segment seems to have returned to a more or less standard consumption model in Q1–Q2 2022, but the segment was still far ahead of the offline channel in terms of growth rates.

The growth rates of veterinary imports to Russia in monetary terms kept falling in January–July 2022. Russia imported 22 billion rubles’ worth of veterinary drugs (customs clearance and VAT included), down 0.8% from January–July 2021, and 25 billion rubles’ worth of feed supplements, down 0.1% from January–July 2021. In physical terms, the growth rate of the import of veterinary drugs was 4.7%, with 19.1 million packages imported. As for feed supplements, the import volume was 80,300 tons, down 16% from January–July 2021.

In January–July 2022, Russia imported 459.4 billion rubles’ worth of ready-made pharmaceutical drugs (customs clearance and VAT included), up 6% from the same period in 2021. As for bulk drugs, the growth rate was 25.6%. In physical terms, the growth rates for both groups were negative. The import volume of ready-made drugs was around 942 million packages, down 10.2% from January–July 2021. If calculated in minimum dosage units (MDU), the import volume of ready-made drugs was 18.2 billion MDUs, down 12.2%. The growth rate of the import of bulk drugs was –32.4% in MDUs, with 903.2 million MDUs imported.

In January–July 2022, Russian manufacturers produced 416.3 billion rubles’ worth of ready-made drugs (manufacturer’s prices, VAT included), up 27.1% from the same period in 2021. In physical terms, the production volume was 2.43 billion packages, up only 4.9% from January–July 2021. If calculated in minimum dosage units (MDU), the volume was 46.1 billion MDUs, 2.5% up from January–July 2021.

In January–July 2022, Russia imported 122 billion rubles’ worth of APIs (customs clearance and VAT included), up 6.1% from January–July 2021. In physical terms, however, the growth rate was as high as 19% (raw materials became cheaper due to ruble revaluation), with 11,300 tons imported.

RNC Pharma: Russian Pharmaceutical Distributors Can Expect Falling Demand, Market Concentration, and E-Com Rise in the Near Future